Alpha Paradigm Partners, LLC Igm Biosciences, Inc. Transaction History
Alpha Paradigm Partners, LLC
- $239 Million
- Q4 2022
Shares
1 transactions
Others Institutions Holding IGMS
# of Institutions
89Shares Held
21.4MCall Options Held
39.5KPut Options Held
16.5K-
Baker Bros. Advisors LP New York, NY4.09MShares$70.6 Million0.37% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.08MShares$70.3 Million0.0% of portfolio
-
Artal Group S.A. Luxembourg, N43.33MShares$57.5 Million1.45% of portfolio
-
Redmile Group, LLC San Francisco, CA3.07MShares$53 Million1.38% of portfolio
-
Goldman Sachs Group Inc New York, NY1.33MShares$23 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $500M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...